Empresa Atossa Genetics Inc Nasdaq
Acciones
US04962H2094
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01/12/08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01/12/08 |
Heather Rees
DFI | Director of Finance/CFO | - | 01/01/17 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 04/12 |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 25/10/22 |
Delly Behen
ADM | Chief Administrative Officer | - | 01/01/14 |
Eric van Zanten
IRC | Investor Relations Contact | - | 07/12/22 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01/12/08 |
Director/Board Member | 66 | 01/03/14 | |
H. Remmel
BRD | Director/Board Member | 72 | 01/02/12 |
Shu-Chih Chen
FOU | Founder | 62 | 01/12/08 |
Stephen Galli
BRD | Director/Board Member | 77 | 01/07/11 |
Jonathan Finn
BRD | Director/Board Member | 50 | 08/11 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 127 077 462 | 125 230 652 ( 98,55 %) | 0 | 98,55 % |
Acción B | 0 | 582 | 0 | 0 |
Información de la empresa
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+29,77 % | 49,46 mil M | |
+1,00 % | 42,58 mil M | |
+50,47 % | 42,49 mil M | |
-5,26 % | 29,09 mil M | |
+13,68 % | 26,61 mil M | |
-22,99 % | 18,64 mil M | |
+8,22 % | 13,16 mil M | |
+32,41 % | 12,55 mil M | |
-1,62 % | 11,98 mil M |